Composite Resources v. Rhino Inc.: ITC Tourniquet Patent Dispute Settles in 151 Days
Composite Resources, Inc. brought a Section 337 infringement action at the US International Trade Commission against Rhino Inc., asserting three US patents covering tourniquet technology and methods of use. The investigation, presided over by ALJ Cameron Elliot, resolved by settlement before reaching a final determination — closing in just 151 days.
Three tourniquet patents, one ITC investigation, resolved before final ruling
On 13 February 2025, Composite Resources, Inc. filed ITC Investigation No. 337-TA-1364 against Rhino Inc., alleging infringement of three US patents — US7842067B2, US8888807B2, and US10016203B2 — all directed to tourniquet devices and associated methods of use. The case was assigned to Administrative Law Judge Cameron Elliot and litigated through King & Spalding LLP for Composite Resources and Akin Gump Strauss Hauer & Feld, LLP for Rhino Inc.
The investigation terminated on 14 July 2025 — 151 days after filing — on the basis that the parties reached a settlement. No final initial determination or exclusion order was issued by the Commission. The confidential settlement means the specific terms, including any licensing arrangement, royalty payment, or product modification commitments, are not reflected in the public record.
The pace of resolution is notable: ITC Section 337 investigations typically proceed to final determination over 16–18 months, making this settlement notably early. Early resolution at the ITC often suggests either meaningful commercial pressure from the threat of an exclusion order or a licensing relationship that was achievable without full merits adjudication. What drove the specific terms — and whether Rhino Inc. secured a licence or agreed to cease importation — cannot be confirmed from the public record.
Filing to Case Settled in 151 days
151 days — faster than typical ITC Section 337 investigations, which average 16–18 months to final determination
ITC investigation settled: what the resolution means for both parties
Section 337 settlements end the investigation without an exclusion order
When parties settle an ITC Section 337 investigation, the Commission terminates the proceeding without issuing an exclusion order or cease-and-desist order. No merits ruling is made on infringement or validity. The settlement is typically memorialised in a consent order or private agreement filed with the Commission. The underlying patents remain fully in force and enforceable in parallel US district court proceedings.
No exclusion order issuedComposite Resources retains enforcement leverage on all three patents
Settlement before a final determination preserves Composite Resources’ three patents without subjecting them to a potentially adverse validity ruling. The patents — US7842067B2, US8888807B2, and US10016203B2 — emerge from the investigation unchallenged on the merits. This strengthens the plaintiff’s position for future enforcement actions against other importers or domestic manufacturers of competing tourniquet products.
Patents intact, enforcement preservedRhino Inc. avoids an exclusion order but settlement terms are undisclosed
By settling, Rhino Inc. avoided the risk of a general exclusion order, which could have barred importation of its tourniquet products. Whether the settlement included a licence, a design-around commitment, or a financial payment is not public. The absence of a final determination also means Rhino did not secure a ruling of non-infringement or invalidity that could have benefited the broader market.
Exclusion order risk avoidedITC settlement signals continued patent pressure in the tourniquet market
The willingness of both parties to settle this quickly — well before a final ITC determination — is consistent with the high commercial stakes of exclusion order risk in the medical device sector. Other manufacturers importing competing tourniquet or emergency haemostatic device products should treat this outcome as a signal that Composite Resources is actively enforcing its portfolio. The three asserted patents span a broad timeframe of application dates and may cover a wide claim scope.
Active portfolio enforcement signalFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Composite Resources, Inc. | Company | Medical device IP holder — holder of US7842067B2, US8888807B2, and US10016203B2Search in Eureka ↗ |
| Defendant | Rhino Inc. | Company | Rhino Inc. — respondent in ITC Section 337 tourniquet infringement investigationSearch in Eureka ↗ |
| Plaintiff counsel | Jeffrey Telep | Attorney | Counsel for Composite Resources, Inc.Search in Eureka ↗ |
| Plaintiff law firm | King & Spalding LLP | Law Firm | Representing Composite Resources, Inc.Search in Eureka ↗ |
| Defendant counsel | Cono A. Carrano | Attorney | Counsel for Rhino Inc.Search in Eureka ↗ |
| Defendant law firm | Akin Gump Straus Hauer & Feld, LLP | Law Firm | Representing Rhino Inc.Search in Eureka ↗ |
| Presiding judge | Judge Cameron Elliot | Judge | United States International Trade CommissionSearch in Eureka ↗ |
Official order — verbatim text
The case terminated on the basis of ‘Case Settled,’ with the participant disposition recorded as ‘Settlement.’ This phrasing confirms that the investigation ended by mutual agreement of the parties rather than by any merits determination. No infringement finding, no invalidity ruling, and no exclusion order was entered. The confidential nature of ITC settlements means the specific commercial terms — including any licensing royalty, supply restriction, or payment — are not ascertainable from the public record. Both parties’ litigation positions on the three asserted patents remain formally untested.
US7842067B2, US8888807B2 & US10016203B2 — Tourniquet Device and Method Patents
The three patents asserted in this investigation — US7842067B2, US8888807B2, and US10016203B2 — relate to tourniquet technology and methods of use, a product category with significant military, law enforcement, and emergency medical applications. The application numbers suggest filings in 2005, 2010, and 2014 respectively, indicating an extended patent prosecution strategy by Composite Resources. Collectively, the patents may protect successive design generations and specific application methods, creating layered claim coverage in the haemorrhage control device space.
Tourniquet patents carry heightened commercial significance given the life-safety nature of the product and substantial government procurement activity in the US defence and emergency medical sectors. A multi-patent portfolio of this kind, held by a specialist manufacturer and actively enforced at the ITC, suggests Composite Resources occupies a strategic IP position in the market. Competitors, contract manufacturers, and importers of tourniquet or haemostatic control devices should treat this portfolio as a credible and demonstrated enforcement risk.
Should your product team run an FTO against US7842067B2, US8888807B2 & US10016203B2?
Any company manufacturing, importing, or distributing tourniquet devices or haemorrhage control products for the US market should consider a structured freedom-to-operate analysis against these three patents. The ITC complaint and early settlement confirm that Composite Resources is prepared to enforce. Given the three-patent stacking approach and the span of application dates, a single-patent clearance review is insufficient — all three must be assessed against your specific product claims.
PatSnap Eureka’s FTO Search Agent allows product and IP teams to map claim language from US7842067B2, US8888807B2, and US10016203B2 against competitor product architectures and identify freedom-to-operate gaps before they become ITC respondent exposure. Use Eureka to track the full Composite Resources patent family, monitor continuation applications, and receive alerts on any new assertion activity in the tourniquet and emergency medical device space.
Run a freedom-to-operate analysis on US7842067B2 to assess your product’s exposure
Run FTO in Eureka →Similar ITC Section 337 cases involving medical device and tourniquet patents
Explore comparable ITC Section 337 investigations involving medical device patents litigated before the US International Trade Commission, including early-settlement and exclusion order outcomes.
What this ITC settlement signals for the tourniquet and medical device IP landscape
An early ITC settlement on three tourniquet patents confirms active enforcement pressure — and raises the stakes for any competing importer.
Early ITC settlement amplifies exclusion order threat for other importers
Composite Resources resolved this investigation before a final determination, but the patents remain fully valid and unreviewed on the merits. Any other importer of tourniquet or haemostatic device products should assess exposure to US7842067B2, US8888807B2, and US10016203B2 now — before an ITC complaint names them as a respondent.
Three-patent assertion strategy strengthens licensing leverage at the ITC
Asserting three patents simultaneously at the ITC — spanning different application dates — increases the difficulty of designing around any single claim. This stacking approach is commonly used to deter early validity challenges and to accelerate settlement. Patent teams monitoring the tourniquet space should map claim scope across all three asserted patents.
Composite v Rhino — key questions answered
ITC Investigation 337-TA-1364 was filed by Composite Resources, Inc. on 13 February 2025 asserting infringement of three US tourniquet patents against Rhino Inc. The case was assigned to ALJ Cameron Elliot and settled on 14 July 2025 — 151 days after filing — before any final determination or exclusion order was issued.
Composite Resources asserted three US patents: US7842067B2, US8888807B2, and US10016203B2. All three relate to tourniquet devices and methods of use. The application numbers suggest filings in 2005, 2010, and 2014, indicating a multi-generation enforcement portfolio spanning the company’s core tourniquet technology.
Settlement in an ITC Section 337 investigation terminates the proceeding without any merits ruling on infringement or patent validity. The asserted patents remain fully in force and have not been subjected to an invalidity finding. The patent holder retains the right to assert the same patents in US district court or in future ITC proceedings against other respondents.
No exclusion order was issued. The investigation terminated by settlement before the ITC ALJ issued an initial determination on the merits. As a result, no exclusion order or cease-and-desist order entered the public record. Whether Rhino Inc. agreed to stop importing the relevant products as part of the private settlement terms is not publicly disclosed.
The case settled in 151 days — significantly faster than the typical 16–18 month timeline for ITC investigations reaching final determination. Early settlements at the ITC typically suggest either a pre-existing licensing relationship, strong claim coverage that made defence commercially unattractive, or a business resolution that avoided the risk of a broad exclusion order. The specific drivers in this case are not publicly disclosed.
PatSnap Eureka searches patents and litigation data to answer instantly.